Skip to main content

Advertisement

SpringerLink
Log in

Evaluation of matrix metalloproteinase-9 plasma levels in untreated new Relapsing–remitting multiple sclerosis patients and their first-degree family

  • Original Article
  • Published:
Metabolic Brain Disease Aims and scope Submit manuscript

Abstract

Matrix metalloproteinase, especially Matrix metalloproteinase-9 (MMP-9) has vital roles in the disruption of blood barrier, neuroinflammation and pathogenesis of multiple sclerosis (MS) patients. The goal of this study is to estimate the plasma levels of MMP-9 in the first-degree family of MS patients. 35 untreated patients with definite RRMS (Relapsing–Remitting Multiple sclerosis) according to the McDonald criteria, 24 healthy controls (HC) and 26 high-risk families of untreated RRMS patients were enrolled in the study. Plasma levels of MMP-9 were analyzed by ELISA (enzyme-linked immunosorbent assay). Although the plasma protein levels of MMP-9 were elevated significantly in the untreated RRMS group (P < 0.05, P = 0.0203) as compared to the control group, but the family of MS patients was not significance (P = 0.208). The mean plasma MMP-9 concentration for HC, untreated RRMS and high-risk group was 322.268 pg/ml, 611.926 pg/ml and 518.939 pg/ml respectively. MMP-9 was used to understand the role of this biomarker in the pathogenesis of MS in the high-risk group. It found that plasma levels of MMP-9 in the new cases of MS were increased considerably. Confirming the importance of MMP-9 as a predictive marker in the high-risk group will be needed more researches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data availability

Derived data supporting the findings of this study are available from the corresponding author on request.

References

  • Avolio C, Ruggieri M, Giuliani F, Liuzzi GM, Leante R, Riccio P, Livrea P, Trojano M (2002) Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes

  • Bove R, McHenry A, Hellwig K, Houtchens M, Razaz N, Smyth P, Tremlett H, Sadovnick AD, Rintell D (2016) Multiple sclerosis in men: management considerations. J Neurol 263:1263–1273.https://doi.org/10.1007/s00415-015-8005-z

  • Buhse M (2015) The elderly person with multiple sclerosis: clinical implications for the increasing life-span. J Neurosci Nurs 47:333–339; quiz E331. https://doi.org/10.1097/JNN.0000000000000172

  • Castellazzi M, Bellini T, Trentini A, Delbue S, Elia F, Gastaldi M, Franciotta D, Bergamaschi R, Manfrinato MC, Volta CA, Granieri E (2016) Serum gelatinases levels in multiple sclerosis patients during 21 months of natalizumab therapy. Disease Markers 8434209https://doi.org/10.1155/2016/8434209

  • Etemadifar M, Sajjadi S, Nasr Z, Firoozeei TS, Abtahi SH, Akbari M, Fereidan-Esfahani M (2013) Epidemiology of multiple sclerosis in Iran: a systematic review. Eur Neurol 70:356–363. https://doi.org/10.1159/000355140

    Article  PubMed  Google Scholar 

  • Gannagé‐Yared MH, Chemali R, Yaacoub N, Halaby G (2000) Hypovitaminosis D in a sunny country: relation to lifestyle and bone markers

  • Garg N, Smith TW (2015) An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. Brain Behav 5:e00362. https://doi.org/10.1002/brb3.362

  • Gu C, Wang F, Hou Z, Lv B, Wang Y, Cong X, Chen X (2017) Sex-related differences in serum matrix metalloproteinase-9 screening non-calcified and mixed coronary atherosclerotic plaques in outpatients with chest pain

  • Hashemipour S, Larijani B, Adibi H, Javadi E, Sedaghat M, Pajouhi M, Soltani A, Shafaei AR, Hamidi Z, Fard AR, Hossein-Nezhad A (2004) Vitamin D deficiency and causative factors in the population of Tehran

  • Jablonska-Trypuc A, Matejczyk M, Rosochacki S (2016) Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J Enzyme Inhib Med Chem 31:177–183. https://doi.org/10.3109/14756366.2016.1161620

  • Koriem KM (2017) Corrigendum to ‘Multiple sclerosis: new insights and trends’. Asian Pac J Trop Biomed 7:493–504. https://doi.org/10.1016/j.apjtb.2017.02.001

  • Lee MA, Palace J, Stabler G, Ford J, Gearing A, Miller K (1999) Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis

  • Leppert D, Ford J, Stabler G, Grygar C, Lienert C, Huber S, Miller KM, Hauser SL, Kappos L (1998) Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis

  • Lindberg RL, De Groot CJ, Montagne L, Freitag P, van der Valk P, Kappos L, Leppert D (2001) The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis

  • Liu X, Cui Y, Han J (2016) Estimating epidemiological data of Multiple sclerosis using hospitalized data in Shandong Province. China Orphanet J Rare Dis 11:73. https://doi.org/10.1186/s13023-016-0457-4

    Article  PubMed  Google Scholar 

  • Lu P, Takai K, Weaver VM, Werb Z (2011) Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol 3. https://doi.org/10.1101/cshperspect.a005058

  • Milo R, Kahana E (2010) Multiple sclerosis: Geoepidemiology, genetics and the environment

  • Mirshafiey A, Asghari B, Ghalamfarsa G, Jadidi-Niaragh F, Azizi G (2014) The significance of matrix metalloproteinases in the immunopathogenesis and treatment of multiple sclerosis

  • Nielsen NM et al (2005) Familial risk of multiple sclerosis: a nationwide cohort study. Am J Epidemiol 162:774–778. https://doi.org/10.1093/aje/kwi280

    Article  PubMed  Google Scholar 

  • O’Gorman C, Lin R, Stankovich J, Broadley SA  (2013) Modelling genetic susceptibility to multiple sclerosis with family data. Neuroepidemiology 40:1–12. https://doi.org/10.1159/000341902

  • Pittayapruek P, Meephansan J, Prapapan O, Komine M, Ohtsuki M (2016) Role of matrix metalloproteinases in photoaging and photocarcinogenesis. Int J Mol Sci 17.https://doi.org/10.3390/ijms17060868

  • Pytel V et al (2018) Familial multiple sclerosis and association with other autoimmune diseases. Brain Behav 8:e00899. https://doi.org/10.1002/brb3.899

    Article  PubMed  Google Scholar 

  • Ramagopalan SV, Dobson R, Meier UC, Giovannoni G (2010) Multiple sclerosis: risk factors, prodromes, and potential causal pathways

  • Reder A (1997) Interferon therapy of multiple sclerosis

  • Robertson NP, Fraser M, Deans J, Clayton D, Walker N, Compston DA (1996) Age-adjusted recurrence risks for relatives of patients with multiple sclerosis

  • Sahebi R, Amiri M, Jami MS (2017) Multiple Sclerosis in Iran International Journal of Epidemiologic Research 5:30–33. https://doi.org/10.15171/ijer.2018.07

    Article  Google Scholar 

  • Singh D, Srivastava SK, Chaudhuri TK, Upadhyay G (2015) Multifaceted role of matrix metalloproteinases (MMPs). Front Mol Biosci 2:19 https://doi.org/10.3389/fmolb.2015.00019

  • Stadelmann C, Wegner C, Bruck W (2011) Inflammation, demyelination, and degeneration - recent insights from MS pathology. Biochim Biophys Acta 1812:275–282.https://doi.org/10.1016/j.bbadis.2010.07.007

  • Sternlicht MD, Werb Z (2001) How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463–516. https://doi.org/10.1146/annurev.cellbio.17.1.463

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Suthreland JM (1956) Observations on the prevalence of multiple sclerosis in Northern Scotland

  • Trentini A, Castellazzi M, Cervellati C, Manfrinato MC, Tamborino C, Hanau S, Volta CA, Baldi E, Kostic V, Drulovic J, Granieri E (2016) Interplay between matrix metalloproteinase-9, matrix metalloproteinase-2, and interleukins in multiple sclerosis patients. Dis Markers 2016:3672353 https://doi.org/10.1155/2016/3672353

  • Valado A, Leitão MJ, Martinho A, Pascoal R, Cerqueira J, Correia I, Batista S, Sousa L, Baldeiras I (2017) Multiple sclerosis: association of gelatinase B/matrix metalloproteinase-9 with risk and clinical course the disease. Mult Scler Relat Disord 11:71–76.https://doi.org/10.1016/j.msard.2016.12.003

  • Verslegers M, Lemmens K, Van Hove I, Moons L (2013) Matrix metalloproteinase-2 and -9 as promising benefactors in development, plasticity and repair of the nervous system. Prog Neurobiol 105:60–78. https://doi.org/10.1016/j.pneurobio.2013.03.004

  • Waubant E, Goodkin DE, Gee L, Bacchetti P, Sloan R, Stewart T, Andersson PB, Stabler G, Miller K (1999) Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 53:1397–1401. https://doi.org/10.1212/wnl.53.7.1397

  • Yin H, Wan Q, Tian Y, Zhao B, Deng Y (2018) Female Hormone 17β-Estradiol Downregulated MMP-2 Expression and Upregulated A1PI Expression in Human Corneal Stromal Cells

  • Zhang G, Wang P, Wang X (2017). Skin ageing and cancer. https://doi.org/10.5772/intechopen.70266

    Article  Google Scholar 

Download references

Acknowledgements

We thank Fasa university of medical science for providing laboratory equipment and also Dr. Azizollah Dehghan for his help in statistical analyzed.

Funding

The authors received no specific funding for this work.

Author information

Authors and Affiliations

  1. Department of Clinical Biochemistry, School of Medicine, University of Medical Sciences, Fasa, Iran

    Mahsa Samangooei, Mojtaba Farjam, Mohammad hasan Meshkibaf & Saam Noroozi

  2. Iran Neurological Associations, Tehran, Iran

    Zahra Niknam

  3. Department of Neurosurgery, Isfahan University of Medical Sciences, Isfahan, Iran

    Masoud Etemadifar

Authors
  1. Mahsa Samangooei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mojtaba Farjam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zahra Niknam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masoud Etemadifar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mohammad hasan Meshkibaf
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Saam Noroozi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Mahsa Samangooei contributed to laboratory tests, analyzed the biochemical data and formatted the data, and helped with manuscript writing. Mojtaba Farjam contributed to revised the manuscript. Dr. Zahra Niknam and Masoud Etemadifar as neurologists helped to collected MS patients. Mohammad Hasan Meshkibaf helped with critically revised the manuscript. Saam Noroozi helped with the conceived, design, and supervised the work, analyzed the in vitro data, and co-wrote the manuscript also critically revised the manuscript.

Corresponding author

Correspondence to Saam Noroozi.

Ethics declarations

Competing interests

The authors declare that they have no conflict of interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Samangooei, M., Farjam, M., Niknam, Z. et al. Evaluation of matrix metalloproteinase-9 plasma levels in untreated new Relapsing–remitting multiple sclerosis patients and their first-degree family. Metab Brain Dis 36, 1929–1934 (2021). https://doi.org/10.1007/s11011-021-00758-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11011-021-00758-9

Keywords

Search

Navigation